ORDERING RELENZA — HOW TO ORDER RELENZA

Guideline 4: Storage — Storage Partners

Anda
2915 Weston Road
Weston, FL 33331
800-331-2632
800-989-0700 (Fax)

Burlington Drug Co.
91 Catamount Drive
Milton, VT 54680

DMS Pharmaceuticals
810 Busse Hwy
Park Ridge, IL 62703

Edwards Medical
495 Woodcreek Drive
Bolingbrook, IL 60440
800-358-2000
630-378-5350 (Fax)
www.edwardsmedical.com

Kinray, Inc.
152-35 10th Ave
Whitestone, NY 11357

Logistics Health, Inc.
328 Front Street South
LaCrosse, WI 54601
866-284-8788
608-783-7532 (Fax)
www.logisticshealth.com

McQueary Brothers
4727 E Kearney
Springfield, MO 65801
800-747-2577
417-831-5207 (Fax)
www.mcqbros.com

Metro Medical Supply, Inc.
200 Cumberland Bend
Nashville, TN 37228
800-768-2002
615-256-4194 (Fax)
www.metromedical.com

PBA Health
1575 N. Universal Avenue
Suite 100
Kansas City, MO 64120
800-333-8097
816-245-5702 (Fax)
www.pbahealth.com

Back

Disclaimer

The Pandemic Planning website contains information on third parties. This information is provided as a service to individuals interested in more information. GSK makes no warranties or representations to third party’s ability under state and local laws to store prescription drug products. All information represented by third parties is self reported.

 
Important Safety Information About RELENZA

• Serious cases of bronchospasm, including fatalities, have been reported during treatment with RELENZA in patients with and without underlying airway disease. Many of these cases were reported during postmarketing, and causality was difficult to assess
  
• RELENZA SHOULD BE DISCONTINUED IN ANY PATIENT WHO DEVELOPS BRONCHOSPASM OR DECLINE IN RESPIRATORY FUNCTION; immediate treatment and hospitalization may be required
  
• Safety and efficacy have not been demonstrated in patients with high-risk underlying medical conditions
  
• Patients should be instructed in the use of the delivery system. Instructions should include a demonstration whenever possible
  
• If treatment with RELENZA is considered for a patient with underlying airway disease, the potential risks and benefits should be carefully weighed. If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care including availability of fast-acting bronchodilators
  
• Common adverse events in treatment and prophylaxis studies with RELENZA were nausea, diarrhea, sinusitis, viral respiratory infections, headaches, nasal signs and symptoms. The incidence of these adverse events was similar in both groups for RELENZA and placebo-treated groups
  
• Please see complete Prescribing Information for RELENZA